CDH3-directed immunotherapy targets basal-like hormone receptor negative prostate cancer and breast cancer
JCI Insight · 03.11.2026
DOI: 10.1172/jci.insight.205779 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 03.11.2026. Verfasst von Guoqiang Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Biomedical Science Graduate Program, University of Notre Dame, Notre Dame, United States of America. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, National Institutes of Health, Mary Kay Foundation.
Abstract (Originalsprache)
Basal-like double-negative prostate cancer (DNPC) and triple-negative breast cancer (TNBC) are aggressive tumors with few targeted treatment options, raising the question of whether a shared, druggable cell-surface antigen can be leveraged for effective immunotherapy. Here, we integrated analyses of independent bulk and single-cell transcriptomic datasets with mechanistic and preclinical therapeutic studies to evaluate CDH3 (P-cadherin) as a candidate target in basal-like disease. CDH3 expression was consistently enriched in basal-like subtypes across prostate and breast cancer cohorts and was preferentially expressed in basal epithelial tumor compartments. Mechanistically, CDH3 expression was governed by a YAP1–WNT5A/ROR2 signaling axis, linking basal subtype gene expression to non-canonical Wnt signaling. To exploit this target, we evaluated both a CDH3-directed antibody-drug conjugate (ADC) and CDH3-specific chimeric antigen receptor (CAR)-T cells. The ADC exhibited antigen-dependent internalization and cytotoxicity in vitro and reduced metastatic tumor burden in vivo . CDH3 CAR-T cells showed antigen-specific activation and tumor cell killing in vitro and improved tumor control and survival in metastatic prostate and breast cancer xenograft models, with additional benefit when combined with PD-1 blockade (nivolumab). Together, these findings establish CDH3 as a clinically relevant and therapeutically actionable target and support CDH3-directed ADC and CAR-T strategies for aggressive, basal-like DNPC and TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Integrated Biomedical Science Graduate Program, University of Notre Dame, Notre Dame, United States of America.
- Department of Biological Sciences, University of Notre Dame, Notre Dame, United States of America.
- iSURE Program, University of Notre Dame, Notre Dame, United States of America.
- Department of Medical and Molecular Genetics, Center for Computational Biol, Indiana University School of Medicine, Indianapolis, United States of America.
- Department of Pathology and Laboratory Medicine, Department of Surgery, Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, and Brown University Health, Providence, United Sta…
Förderung
- U.S. Department of Defense
- National Institutes of Health
- Mary Kay Foundation
- Walther Cancer Foundation
Zitieren
APA
Liu, G., Wang, S., Zeng, Z., Duong, L., Yang, J., Barupala, N., Zhao, Y., Rahmy, S., Feng, S., Chi, X., Arce, A., Jia, L., Wan, J., Cheng, L., Lu, X., & Lu, X. (2026). CDH3-directed immunotherapy targets basal-like hormone receptor negative prostate cancer and breast cancer. JCI Insight. https://doi.org/10.1172/jci.insight.205779
Vancouver
Liu G, Wang S, Zeng Z, Duong L, Yang J, Barupala N, et al. CDH3-directed immunotherapy targets basal-like hormone receptor negative prostate cancer and breast cancer. JCI Insight. 2026. doi:10.1172/jci.insight.205779
BibTeX
@article{Liu2026,
author = {Liu, Guoqiang and Wang, Shiyu and Zeng, Ziyu and Duong, Loan and Yang, Jing and Barupala, Nipuni and Zhao, Yun and Rahmy, Sharif and Feng, Shan and Chi, Xiaotian and Arce, Ariana and Jia, Linchuan and Wan, Jun and Cheng, Liang and Lu, Xuemin and Lu, Xin},
title = {CDH3-directed immunotherapy targets basal-like hormone receptor negative prostate cancer and breast cancer},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.205779}
}
EUVIMED